Carillon Tower Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Carillon Tower Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$6.16M	Sell	99,300 -3,600	-3%	-$221K	0.04%	390
2020 Q3	$6.2M	Sell	102,900 -7,900	-7%	-$475K	0.08%	306
2020 Q2	$6.51M	Sell	110,800 -7,200	-6%	-$431K	0.05%	347
2020 Q1	$6.58M	Buy	118,000 +43,000	+57%	+$2.63M	0.06%	318
2019 Q4	$4.81M	Buy	+75,000	New	+$4.3M	0.03%	395

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Carillon Tower Advisers's BMY Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Bristol-Myers Squibb (BMY) stake by 3.5% in Q4 2020, selling an estimated $221K and leaving 99,300 shares worth $6.16M. The position accounts for 0.04% of the portfolio, ranked #390.

Carillon Tower Advisers first reported a position in BMY in Q4 2019 and has held it in 5 quarters since. The position peaked at $6.58M in Q1 2020. 2,361 funds tracked by Wall St. Rank hold BMY as of Q4 2020.

Carillon Tower Advisers held 99,300 shares of Bristol-Myers Squibb worth $6.16M as of Q4 2020.
Carillon Tower Advisers sold 3,600 Bristol-Myers Squibb shares in Q4 2020, an estimated $221K.
Bristol-Myers Squibb made up 0.04% of Carillon Tower Advisers's portfolio in Q4 2020, its #390 holding.
Carillon Tower Advisers first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 5 quarters since.
Carillon Tower Advisers's Bristol-Myers Squibb position peaked at $6.58M in Q1 2020.
2,361 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.